49 completed, 32 unknown, 24 recruiting, 12 active not recruiting. 39 Phase 4, 14 Phase 3, 11 Not applicable, 11 Phase 2, 7 Phase 1.
Follow this drug Literature Review of Sodium-Glucose Transporter 2 Inhibitors trials Research Report on Sodium-Glucose Transporter 2 Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glycemic Velocity and Early Retinal Microvascular Change With GLP-1RA Versus SGLT2i Initiation in Type 2 Diabetes (GLIDE) GLP-1 Receptor Agonists, SGLT2 inhibitor - Type 2 Diabetes Mellitus, Diabetic Retinopathy (DR) | Not yet recruiting | Thammasat University Hospital | 126 | 2026-09-01 | 2026-08-31 | |
| Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes SGLT-2 inhibitor and Chiglitazar, SGLT-2 inhibitor and Other Oral Antidiabetic Drugs (OADs) - T2DM (Type 2 Diabetes Mellitus) | Not yet recruiting | Chipscreen Biosciences, Ltd. | 3550 | 2026-07-18 | 2026-05-12 | |
| Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy SGLT-2 inhibitor, SGLT2 inhibitor - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Recruiting | Vanderbilt University Medical Center | 10 | 2026-07-01 | 2026-08-24 |
| SGLT2 Inhibitors and Cognitive Function in Adults With Type 2 Diabetes (SaveMinD) SGLT2 Inhibitor, Standard Diabetes Care - Type 2 Diabetes Mellitus (T2DM), Cognitive Dysfunction | Not applicable | Active not recruiting | University of Primorska | 200 | 2026-06-20 | 2026-07-10 |
| Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors SGLT-2 inhibitor (Sotagliflozin), Insulin withdrawal test (IWT) - Type 1 Diabetes, Type 2 Diabetes | Phase 2 | Not yet recruiting | AdventHealth Translational Research Institute | 75 | 2026-06-01 | 2026-02-19 |
| Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study Sacubitril / Valsartan, SGLT-2 inhibitor, SGLT2 Inhibition - Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy | Phase 4 | Recruiting | Kyungsub Song | 80 | 2026-05-20 | 2026-09-02 |
| Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure GDMT, Quality of life questionnaire - Heart Failure | Recruiting | Università Vita-Salute San Raffaele | 300 | 2026-05-08 | 2026-07-06 | |
| GLP1 Analogues and the Risk of Osteoarthritis GLP-1 analog, SGLT2 inhibitor, Antidiabetic - Osteoarthritis | Not yet recruiting | Beni-Suef University | 390 | 2026-02-01 | 2026-01-22 | |
| Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR Henagliflozin (SGLT2 Inhibitor), Placebo - HCM - Hypertrophic Cardiomyopathy | Not applicable | Not yet recruiting | Shanghai East Hospital | 150 | 2026-01-07 | 2025-12-19 |
| Effect of SGLT2 Inhibitors on Anemic CKD Patients SGLT2 inhibitor - Anemia in CKD Patients | Not yet recruiting | Sohag University | 60 | 2026-01-01 | 2026-01-14 | |
| SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes SGLT-2 inhibitor, Sham (No Treatment) - Lung Cancer | Not applicable | Not yet recruiting | Shanghai Chest Hospital | 200 | 2025-12-07 | 2025-12-09 |
| Transformative Research in Diabetic Nephropathy 2.0 Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA) - Diabetic Nephropathies, Kidney Diseases | Recruiting | University of Pennsylvania | 200 | 2025-11-12 | 2026-03-02 | |
| SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients SGLT-2 inhibitor, Placebo - Kidney Transplantation Recipients, Sodium-Glucose Transporter 2 Inhibitors | Phase 4 | Recruiting | Odense University Hospital | 88 | 2025-09-01 | 2025-08-27 |
| SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated Vasculitis Gliflozin - Lupus Nephritis (LN), ANCA Associated Vasculitis (AAV) | Phase 4 | Not yet recruiting | Federico II University | 40 | 2025-09-01 | 2025-06-25 |
| The Use of Advanced Imaging in HFpEF Advanced imaging, SGLT-2 inhibitor - Heart Failure With Preserved Ejection Fraction (HFPEF) | Recruiting | Sheffield Teaching Hospitals NHS Foundation Trust | 40 | 2025-08-05 | 2026-03-18 | |
| SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke SGLT-2 inhibitors, Standard medical treatment - Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 1050 | 2025-08-01 | 2025-08-11 |
| SGLT2 Inhibitors and Renal Anemia in Japan: RWD SGLT2 inhibitor - Chronic Kidney Disease | Active not recruiting | Boehringer Ingelheim | 15000 | 2025-07-23 | 2026-09-16 | |
| Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors Treatment with SGLT2 inhibitors (flozins) - Peripheral Arterial Disease(PAD) | Recruiting | Wroclaw Medical University | 300 | 2025-07-01 | 2026-03-23 | |
| Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial SGLT2 inhibitor (Dapagliflozin 10mg) - Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF) | Phase 4 | Recruiting | The University of Hong Kong | 106 | 2025-05-12 | 2025-05-20 |
| Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome Tadalafil 5 mg, SGLT-2 inhibitor, Tadalafil plus SGLT2 inhibitors - Erectile Dysfunction, Left Ventricular Diastolic Dysfunction | Phase 4 | Completed | Kafrelsheikh University | 60 | 2025-05-05 | 2026-05-04 |
Showing 20 of 133. Sign in to see all of them.
Diabetes Mellitus, Type 2 (48) · Diabetes Mellitus (18) · Heart Failure (17) · Renal Insufficiency, Chronic (9) · Cardiovascular Diseases (5) · Atrial Fibrillation (4) · Diabetic Nephropathies (4) · Hypertension (4) · Myocardial Infarction (4) · Obesity (4) · Acute Kidney Injury (3) · Diabetes Mellitus, Type 1 (3) · Insulin Resistance (3) · Ketosis (3) · Kidney Diseases (3)
Assiut University (5) · Samsung Medical Center (4) · Brigham and Women's Hospital (3) · Sanofi (3) · Yonsei University (3) · AdventHealth Translational Research Institute (2) · Ain Shams University (2) · Boehringer Ingelheim (2) · Eli Lilly and Company (2) · Fayoum University (2) · Federico II University (2) · Jeil Pharmaceutical Co., Ltd. (2) · Kafrelsheikh University (2) · Sequana Medical N.V. (2) · Shanghai 10th People's Hospital (2)
United States (29) · South Korea (15) · China (12) · Italy (12) · Egypt (10) · Spain (6) · United Kingdom (6) · Germany (5) · Hungary (5) · Japan (5) · Netherlands (4) · Russia (4) · Taiwan (4) · Canada (3) · Czechia (3)
Bassem Zarif, MD (2) · Ahmed G Bakry, MD (1) · Alexey Medvedchikov, +43180105-7896 (1) · Alvin Mushlin (1) · Ana Checa-Ros, MD, PhD (1) · Anastasia D. Egorova, MD PhD (1) · Andrew T Hattersley, FRCP, DM, BM (1) · Anna Maria Scandroglio, MD (1) · Anton Cheng, MBBS (1) · Asmaa Elsayed (1) · Ayman Ibrahem, MD (1) · Benjamin M Scirica, MD MPH (1)
PMID 32970396, PMID 37435053, PMID 15851648, PMID 15963399, PMID 17533019, PMID 17572925, PMID 17978307, PMID 19571790, PMID 19571791, PMID 20607462, PMID 20970202, PMID 21440872, PMID 21606384, PMID 21852672, PMID 21885793, PMID 22030444, PMID 22166847, PMID 22237748, PMID 22980301, PMID 22997344, PMID 23624546, PMID 23668478, PMID 23735727, PMID 24029421, PMID 24334175, PMID 25018935, PMID 25585823, PMID 26114442, PMID 26161452, PMID 26240596, PMID 26321369, PMID 26378978, PMID 26630142, PMID 27402170, PMID 27802313, PMID 27822054, PMID 28341274, PMID 28605608, PMID 28606345, PMID 28763548, PMID 29222139, PMID 29483060, PMID 29663436, PMID 29766812, PMID 30177015, PMID 30348145, PMID 30415602, PMID 30559238, PMID 30691124, PMID 30866088
2015 (3), 1OT2HL156812-01 (1), 2014 (1), R61HL180327 (1)